Conversely, high level of genomic gain for the HER2 gene detected by FISH was found to be a significant predictor of outcome to gefitinib and an enhancer of sensitivity to gefitinib in EGFR FISH positive NSCLC patients [38]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.